New Drug's heart risk checked in healthy volunteers
NCT ID NCT06649942
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 26 times
Summary
This study tested whether a new drug called KP-001 affects the heart's electrical activity (QT interval) in 40 healthy adults. Participants received single doses of KP-001, a placebo, or moxifloxacin (a known heart-effect drug) in random order. The goal was to check for heart rhythm changes, not to treat any disease. Results help ensure the drug's safety before further testing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS - MALE AND FEMALE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Parexel Early Phase Clinical Unit - Los Angeles
Glendale, California, 91206, United States
Conditions
Explore the condition pages connected to this study.